ATHENS, Greece, April 26, 2018 -- Diana Containerships Inc. (NASDAQ:DCIX), (the “Company”), a global shipping company specializing in the ownership of containerships, today announced that its financial results for the first quarter ended March 31, 2018 are scheduled to be released before the opening of the U.S. financial markets on May 9, 2018.
About the Company
Diana Containerships Inc. is a global provider of shipping transportation services through its ownership of containerships. The Company’s vessels are employed primarily on time charters with leading liner companies carrying containerized cargo along worldwide shipping routes.
Corporate Contact: Ioannis Zafirakis Director, Chief Operating Officer and Secretary Telephone: +30-216-600-2400 Email: [email protected] Website: www.dcontainerships.com Investor and Media Relations: Edward Nebb Comm-Counsellors, LLC Telephone: + 1-203-972-8350 Email: [email protected]


SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 



